Cited by 1,059Lung Cancer Treatments and MutationsHER2/EGFR in Cancer ResearchCancer Genomics and Diagnostics

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC

Open access

Turke, Alexa B., Zejnullahu, Kreshnik, Wu, Yi-Long, Song, Youngchul, Dias-Santagata, Dora, Lifshits, Eugene, Toschi, Luca, Rogers, Andrew, Mok, Tony, Sequist, Lecia, Lindeman, Neal I., Murphy, Carly, Akhavanfard, Sara, Yeap, Beow Y., Xiao, Yun, Capelletti, Marzia, Iafrate, A. John, Lee, Charles, Christensen, James G., Engelman, Jeffrey A., Jänne, Pasi A.·2010·Cancer Cell

DOI 10.1016/j.ccr.2009.11.022PMC PMC2980857

Open this paper in CoChat — free account Open PDF

Abstract

MET amplification activates ERBB3/PI3K/AKT signaling in EGFR mutant lung cancers and causes resistance to EGFR kinase inhibitors. We demonstrate that MET activation by its ligand, HGF, also induces drug resistance, but through GAB1 signaling. Using high-throughput FISH analyses in both cell lines and in patients with lung cancer, we identify subpopulations of cells with MET amplification prior to drug exposure. Surprisingly, HGF accelerates the development of MET amplification both in vitro and in vivo. EGFR kinase inhibitor resistance, due to either MET amplification or autocrine HGF production, was cured in vivo by combined EGFR and MET inhibition. These findings highlight the potential to prospectively identify treatment naive, patients with EGFR-mutant lung cancer who will benefit from initial combination therapy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.ccr.2009.11.022

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Self-citation
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Self-citation
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
Demetri, G. D., von Mehren, M., Blanke, C. D., Van den Abbeele, A. D., Eisenberg, B., Roberts, P. J., Heinrich, M. C., Tuveson, D. A., Singer, S., Janicek, M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020461 · Cited by 4,389
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527 · cited 2×
“Secondary mutations in EGFR itself, including the EGFR T790M ‘‘gatekeeper’’ mutation is observed in 50% of resistance cases, and amplification of the MET oncogene is observed in 20% of resistance cases (Balak et al., 2006; Bean et al., 2007; Engelman et al., 2007b; Kobayashi et al., 2005; Kosaka et al., 2006; Pao et a…”
Background
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104
Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome
Druker, B. J., Sawyers, C. L., Kantarjian, H., Resta, D. J., Reese, S. F., Ford, J. M., Capdeville, R., & Talpaz, M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441402 · Cited by 2,713
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
Rosell, R., Moran, T., Queralt, C., Porta, R., Cardenal, F., Camps, C., Majem, M., Lopez-Vivanco, G., Isla, D., Provencio, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904554 · Cited by 2,373
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
Yun, C.-H., Mengwasser, K. E., Toms, A. V., Woo, M. S., Greulich, H., Wong, K.-K., Meyerson, M., & Eck, M. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709662105 · Cited by 2,118 · cited 2×
“To date, resistance mechanisms have predominately involved secondary genomic alterations in the target kinase that alter either the physical (such as steric hindrance) or biochemical (change in ATP affinity) properties of the receptor and result in drug resistance (Gorre et al., 2001; Shah et al., 2002; Yun et al., 20…”
Background
Detection of Mutations in EGFR in Circulating Lung-Cancer Cells
Maheswaran, S., Sequist, L. V., Nagrath, S., Ulkus, L., Brannigan, B., Collura, C. V., Inserra, E., Diederichs, S., Iafrate, A. J., Bell, D. W., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0800668 · Cited by 1,617
Self-citation

Show all 37 references

Sorted by citations

Items 801–900 of 1,000

Alterations in EGFR and related genes following neo-adjuvant chemotherapy in Chinese patients with non-small cell lung cancer
Wang, S., An, T., Duan, J., Zhang, L., Wu, M., Zhou, Q., Chen, J., Zhuo, M., Yang, L., Wang, Y., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0051021 · Cited by 7
Bispecific antibody for lung cancer: mechanisms and clinical insights
Chen, W., Zhou, A., & Zhou, Y. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1572802 · Cited by 7
The Role of Reactive Oxygen Species in Lung Cancer Development: Nanomedicine as a Therapeutic Strategy
Olazábal-Morán, M., Pérez, E., Esteban-Arranz, A., & Garrido, A. (2025) · Biomolecules · doi:10.3390/biom15091316 · Cited by 7
EGFR Inhibitors as the First-Line Systemic Treatment for Advanced Non-Small-Cell Lung Cancer
Kao, H., Lin, C., & Yang, J. C. (2013) · Future Oncology · doi:10.2217/fon.13.56 · Cited by 7
Mechanism-Driven Design of Multispecific Antibodies for Targeted Disease Treatment
Fine, J., Meksiriporn, B., Tan, J., & Spangler, J. B. (2024) · Annual Review of Chemical and Biomolecular Engineering · doi:10.1146/annurev-chembioeng-100522-102155 · Cited by 7
Update in Lung Cancer and Oncological Disorders 2010
Halmos, B., & Powell, C. A. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201103-0370up · Cited by 7
Genetic alterations in epidermal growth factor receptor‑tyrosine kinase inhibitor‑na�ve non‑small cell lung carcinoma
Yamaura, T., Muto, S., Mine, H., Takagi, H., Watanabe, M., Ozaki, Y., Inoue, T., Fukuhara, M., Okabe, N., Matsumura, Y., et al. (2020) · Oncology Letters · doi:10.3892/ol.2020.11524 · Cited by 8
Yang-Yin-Jie-Du decoction overcomes gefitinib resistance in non-small cell lung cancer via down-regulation of the PI3K/Akt signalling pathway
Chen, S., Zhang, G.-C.-X., & Shu, Q. (2021) · Pharmaceutical Biology · doi:10.1080/13880209.2021.1972122 · Cited by 7
A quantitative view of strategies to engineer cell-selective ligand binding
Tan, Z. C., Orcutt-Jahns, B. T., & Meyer, A. S. (2021) · Integrative Biology · doi:10.1093/intbio/zyab019 · Cited by 7
Comprehensive analysis of CXCR family members in lung adenocarcinoma with prognostic values
Hu, L.-T., Deng, W.-J., Chu, Z., Sun, L., Zhang, C., Lu, S., Weng, J., Ren, Q.-S., Dong, X., Li, W., et al. (2022) · BMC Pulmonary Medicine · doi:10.1186/s12890-022-02051-6 · Cited by 7
Combinations of EGFR and MET inhibitors reduce proliferation and invasiveness of mucosal melanoma cells
Simiczyjew, A., Wądzyńska, J., Kot, M., Ziętek, M., Matkowski, R., Hoang, M. P., Donizy, P., & Nowak, D. (2023) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.17935 · Cited by 7
Rationale for Targeting the ErbB Family of Receptors in Patients with Advanced Squamous Cell Carcinoma of the Lung
Hall, P. E., Spicer, J. F., & Popat, S. (2015) · Future Oncology · doi:10.2217/fon.15.110 · Cited by 7
[Clinical Observation of Translating to Small Cell Lung Cancer Following Treatment with EGFR-Tyrosine Kinase Inhibitors in Lung Adenocarcinoma].
Xue, S., Yu, T., Zhang, Y., & Li, S. (2015) · Europe PMC (PubMed Central) · doi:10.3779/j.issn.1009-3419.2015.10.10 · Cited by 7
Multiple Growth Factor Targeting by Engineered Insulin-like Growth Factor Binding Protein-3 Augments EGF Receptor Tyrosine Kinase Inhibitor Efficacy
Wang, E. A., Chen, W.-Y., & Wong, C. (2020) · Scientific Reports · doi:10.1038/s41598-020-59466-6 · Cited by 10
High-level gain of mesenchymal-epithelial transition factor (MET) copy number using next-generation sequencing as a predictive biomarker for MET inhibitor efficacy
Wu, S., Li, G., Zhao, X., Xiang, J., Lizaso, A., Ye, J., Shi, C., & Chen, L. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-2741 · Cited by 7
Serum Heparan Sulfate Concentration is Correlated with the Failure of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment in Patients with Lung Adenocarcinoma
Nishio, M., Yamanaka, T., Matsumoto, K., Kimura, H., Sakai, K., Sakai, A., Sone, T., Horiike, A., Koizumi, F., Kasahara, K., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182286d41 · Cited by 7
Optimizing response to gefitinib in the treatment of non-small-cell lung cancer
Normanno, N., Carotenuto, P., Roma, C., Rachiglio, A. M., Pasquale, R., Franco, R., Antinolfi, G., Piantedosi, Illiano, Botti, G., et al. (2011) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s6626 · Cited by 7
Targeted therapies in cancer and mechanisms of resistance
Corso, S., & Giordano, S. (2014) · Journal of Molecular Medicine · doi:10.1007/s00109-014-1171-0 · Cited by 7
Heterogeneity in Tumors and Resistance to EGFR TKI Therapy—Letter
Suda, K., Rivard, C. J., Mitsudomi, T., & Hirsch, F. R. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2916 · Cited by 7
Mechanisms of action of EGFR inhibitors
Normanno, N., Pergameno, M., Lannaccone, A., & Luca, A. D. (2012) · doi:10.2217/ebo.11.305 · Cited by 7
Savolitinib Plus Osimertinib in Epidermal Growth Factor Receptor-Mutated, MET-Amplified Advanced Non-Small Cell Lung Cancer: A Randomized Phase II trial
Yang, J. C., Chen, Y., Batra, U., Hung, K. D., Sitthideatphaiboon, P., Danchaivijitr, P., Lee, K.-Y., Chindaprasirt, J., Yang, C., Chang, G.-C., et al. (2025) · Clinical Lung Cancer · doi:10.1016/j.cllc.2025.10.018 · Cited by 6
Tumor evolution-targeted nanomedicineEVT
Zhang, L., Yang, J., Tang, D., Zhang, H., Ding, J., & Xiao, H. (2022) · Scientia Sinica Chimica · doi:10.1360/ssc-2022-0158 · Cited by 6
Stratified medicine for cancer therapy
Shaw, E. C., & Johnson, P. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.02.004 · Cited by 7
Comparison of the efficacy and safety of single-agent erlotinib and doublet molecular targeted agents based on erlotinib in advanced non-small cell lung cancer (NSCLC): a systematic review and meta-analysis
Pan, G., Ke, S., & Zhao, J. (2013) · Targeted Oncology · doi:10.1007/s11523-013-0272-y · Cited by 7
Hepatic metastasis is a poor predictive marker for erlotinib in lung adenocarcinoma
He, Y., Wang, Y., Zhang, S., Ren, S., Li, J., & Zhou, C. (2016) · Medical Hypotheses · doi:10.1016/j.mehy.2016.06.009 · Cited by 6
Synthesis, Evaluation, and Mechanism Study of New Tepotinib Derivatives as Antiproliferative Agents
Zhang, N., An, B., Zhou, Y., Li, X., & Yan, M. (2019) · Molecules · doi:10.3390/molecules24061173 · Cited by 6
Amivantamab: A Potent Novel EGFR/c-MET Bispecific Antibody Therapy for EGFR -mutated Non-small Cell Lung Cancer
Guo, M. Z., Marrone, K. A., Spira, A. I., Freeman, K., & Scott, S. C. (2021) · touchREVIEWS in Oncology & Haematology · doi:10.17925/ohr.2021.17.1.42 · Cited by 7
Activation of the HSP27-AKT axis contributes to gefitinib resistance in non-small cell lung cancer cells independent of EGFR mutations
Choi, S.-K., Kim, M., Lee, H., Kwon, Y., Cha, H., Jang, S. J., Na, Y., & Lee, Y. (2022) · Cellular Oncology · doi:10.1007/s13402-022-00696-3 · Cited by 6
Genome-wide chemical mutagenesis screens allow unbiased saturation of the cancer genome and identification of drug resistance mutationsPreprint
Brammeld, J. S., Petljak, M., Martincorena, I., Williams, S. P., García‐Alonso, L., Dalmases, A., Bellosillo, B., Robles‐Espinoza, C. D., Price, S., Barthorpe, S., et al. (2016) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/066555 · Cited by 6
Targeting PRMT1 Reduces Cancer Persistence and Tumor Relapse in EGFR - and KRAS -Mutant Lung Cancer
Sun, X., Kumbier, K., Gayathri, S., Steri, V., Wu, L. F., & Altschuler, S. J. (2024) · Cancer Research Communications · doi:10.1158/2767-9764.crc-24-0389 · Cited by 6
The Effects of Silibinin Combined With EGFR ‐ TKIs in the Treatment of NSCLC
Wang, X. (2025) · Cancer Medicine · doi:10.1002/cam4.70643 · Cited by 5
MET signaling drives acquired resistance to erdafitinib in muscle-invasive bladder cancer cells
Makabe, S., Hoshi, K., Kaneko, H., Masuishi, Y., Yaginuma, K., Meguro, S., Onagi, A., Hoshi, S., Hata, J., Ito, H., et al. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-08221-8 · Cited by 6
TRPV1 inhibition sensitizes tumors to PD-1 blockade by reversing resistance to CTL-mediated killing
Son, M. K., Lee, H.-J., Cho, E., Oh, S. J., & Kim, T. W. (2025) · Scientific Reports · doi:10.1038/s41598-025-07120-4 · Cited by 5
Rilotumumab Resistance Acquired by Intracrine Hepatocyte Growth Factor Signaling
Cecchi, F., Rex, K. L., Schmidt, J., Vocke, C. D., Lee, Y. H., Burkett, S. S., Baker, D., Damore, M. A., Coxon, A., Burgess, T. L., et al. (2023) · Cancers · doi:10.3390/cancers15020460 · Cited by 5
Functional Heterogeneity in MET Pathway Activation in PDX Models of Osimertinib-resistant EGFR-driven Lung Cancer
Roper, N., Meskini, R. E., Maity, T. K., Atkinson, D., Day, A., Pate, N., Cultraro, C. M., Pack, S., Zgonc, V., Ohler, Z. W., et al. (2024) · Cancer Research Communications · doi:10.1158/2767-9764.crc-23-0321 · Cited by 5
Molecular Pathology of Non–Small Cell Lung Cancer
Serracino, H. S., Franklin, W. A., & Aisner, D. L. (2012) · Surgical pathology clinics · doi:10.1016/j.path.2012.08.006 · Cited by 5
[Mechanism of c-MET in Non-small Cell Lung Cancer and Its Treatment and Testing].
Liang, H., & Wang, M. (2015) · Europe PMC (PubMed Central) · doi:10.3779/j.issn.1009-3419.2015.12.06 · Cited by 5
The MET Receptor Family
Gao, C., & Woude, G. F. V. (2015) · Springer eBooks · doi:10.1007/978-3-319-11888-8_8 · Cited by 5
Genomics-Based Cancer Theranostics
Yin, Z., Mancuso, J. J., Li, F., & Wong, S. T. C. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-407722-5.00002-5 · Cited by 5
Pulmonary Adenocarcinoma—Pathology and Molecular Testing
Pal, P., Cabanero, M., & Tsao, M. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-55433-6.00002-x · Cited by 5
RevisitingMET: Clinical Characteristics and Treatment Outcomes of Patients with Locally Advanced or Metastatic,MET-Amplified Esophagogastric Cancers
Chaudhary, S. P., Kwak, E. L., Hwang, K. L., Lennerz, J. K., Corcoran, R. B., Heist, R. S., Russo, A. L., Parikh, A. R., Borger, D. R., Blaszkowsky, L. S., et al. (2020) · The Oncologist · doi:10.1634/theoncologist.2020-0274 · Cited by 5
Self-citation
Systems approaches to uncovering the contribution of environment-mediated drug resistance
Creixell, M., Kim, H., Mohammadi, F., Peyton, S. R., & Meyer, A. S. (2022) · Current Opinion in Solid State and Materials Science · doi:10.1016/j.cossms.2022.101005 · Cited by 5
Tepotinib
Schadt, O., & Blaukat, A. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12468-0 · Cited by 5
Preclinical Modeling of Pathway-Targeted Therapy of Human Lung Cancer in the MousePreprint
Vaishnavi, A., Kinsey, C. G., & McMahon, M. (2023) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041385 · Cited by 5
Systematic Engineering of TROP2-Targeted CAR T-Cell Therapy Overcomes Resistance Pathways in Solid Tumors
Brea, E. J., Baldacci, S., Savage, N. J., Facchinetti, F., Hinchey, C., Chakravarti, S., Mottram, A., Ngo, K. H., Vo, H. V., Leeper, B. A., et al. (2025) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-25-0527 · Cited by 4
Targeting PPP1R15B and ATF4 axis in hepatocellular carcinoma: A novel strategy for overcoming lenvatinib-tolerant persister cells through GPX4-mediated ferroptosis induction
Chen, M.-Y., Lai, S., Cheng, Y., Yadav, V. K., Fong, I.-H., Kuo, K.-T., Lee, K., & Cherng, Y. (2026) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2026.107434 · Cited by 4
The Role of Cytokines in Activation of Tumour-promoting Pathways and Emergence of Cancer Drug Resistance
Shirbhate, E., Singh, V. P., Kore, R., Vishwakarma, S., Veerasamy, R., Tiwari, A. K., & Rajak, H. (2024) · Current Topics in Medicinal Chemistry · doi:10.2174/0115680266284527240118041129 · Cited by 4
Identification of AXL as a novel positive regulator of lipid raft in gastric cancer
Yang, Z. G., Ren, C., He, Z., Luo, B., Chen, X., Xu, E., Guan, W., & Xia, X. (2024) · Cellular Signalling · doi:10.1016/j.cellsig.2024.111573 · Cited by 4
Early On-Treatment Prediction of the Mechanisms of Acquired Resistance to EGFR Tyrosine Kinase Inhibitors
Choi, Y., Cho, Y., Park, S.-Y., Kim, S., Shin, M., Choi, Y., Shin, D. H., Han, J., & Lee, Y. (2022) · Cancers · doi:10.3390/cancers14061512 · Cited by 4
Bevacizumab Combined with Continuation of EGFR-TKIs in NSCLC Beyond Gradual Progression
Xu, Z., Teng, F., Hao, X., Li, J., & Xing, P. (2022) · Cancer Management and Research · doi:10.2147/cmar.s363446 · Cited by 4
Recent Advancement in Drug Designing as Small Molecules in Targeted Cancer Therapy: Challenges and Future Directions
Prakash, S., Tyagi, P., Singh, P., Rajkumar, R., & Singh, A. P. (2024) · Current Cancer Drug Targets · doi:10.2174/0115680096331827240911165227 · Cited by 8
Clinical outcomes of EGFR-TKI in advanced lung squamous cell carcinoma and EGFR-TKI remodel tumor immune microenvironment
Chen, Z., Gong, J., Chen, J. W., Yang, L., Hu, S., Chen, L., & Lu, H. (2025) · Annals of Medicine · doi:10.1080/07853890.2025.2488109 · Cited by 4
Distinct evolutionary paths to TKI resistance in NSCLC
Niederst, M. J., Engelman, J. A., & Hata, A. N. (2016) · Cell Cycle · doi:10.1080/15384101.2016.1221024 · Cited by 4
Self-citation
A graph-based algorithm for estimating clonal haplotypes of tumor sample from sequencing data
Wang, Y., Zhang, X., Ding, S., Geng, Y., Liu, J., Zhao, Z., Zhang, R., Xiao, X., & Wang, J. (2019) · BMC Medical Genomics · doi:10.1186/s12920-018-0457-4 · Cited by 4
Stability of EPSPS gene copy number in Hordeum glaucum Steud (barley grass) in the presence and absence of glyphosate selection
Adu‐Yeboah, P., Malone, J. M., Gill, G., & Preston, C. D. (2021) · Pest Management Science · doi:10.1002/ps.6367 · Cited by 4
Optimal treatment strategy of cancers with intratumor heterogeneity
Zhang, H., & Lei, J. (2022) · Mathematical Biosciences & Engineering · doi:10.3934/mbe.2022625 · Cited by 4
The Combined Therapy of Cabozantinib, Crizotinib, and Osimertinib in a Lung Cancer Patient with Acquired MET Amplification and Resistance Mutations
Jóri, B., Vössing, C., Pirngruber, J., Willing, E., Arndt, K., Falk, M., Tiemann, M., Heukamp, L. C., & Hoffknecht, P. (2023) · Current Oncology · doi:10.3390/curroncol30100635 · Cited by 5
Significance of micro-EGFR T790M mutations on EGFR-tyrosine kinase inhibitor efficacy in non-small cell lung cancer
Masuda, T., Miura, S., Sato, Y., TACHIHARA, M. Y., Bessho, A., Nakamura, A., Miyawaki, T., Yoshimine, K., Mori, M., Shiraishi, H., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-45337-3 · Cited by 6
[Research progress of HGF/MET signaling pathway in EGFR-TKI resistance in non-small cell lung cancer].
Song, S., & Bi, M. (2014) · Europe PMC (PubMed Central) · doi:10.3779/j.issn.1009-3419.2014.10.08 · Cited by 4
Highly Active Antitumor Therapy (HAATT) for Epidermal Growth Factor Receptor–Mutant Lung Cancer
Chmielecki, J., & Pao, W. J. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2405 · Cited by 4
Lung Cancer
Jamal‐Hanjani, M., & Lee, S. M. (2015) · Lung Cancer Management · doi:10.2217/lmt.15.11 · Cited by 3
NNMT-driven metabolic reprogramming creates a NAMPT druggable vulnerability and reveals liquid biopsy biomarkers for TKI resistance in EGFR-mutant NSCLC
Pulido, I., García‐Cañaveras, J. C., Rodríguez, M. L., Becker, J. H., López, A., Aupí, M., Aparisi, S., Chuliá‐Peris, L., Tamayo-Torres, E., Carreres-Rey, C., et al. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.218032 · Cited by 3
Marsdenia tenacissima extract potentiates the anti-lung cancer efficacy of gefitinib through dual regulation of the Wnt pathway and ferroptosis
Yang, L., Ren, A., Wang, X., Chen, S., Ni, S., Wang, Y., Li, X., Liao, Q., Li, J., Su, X., et al. (2025) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2025.121121 · Cited by 3
[Research progress on resistance mechanisms of epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer].
Li, Y., & Song, L. (2012) · Europe PMC (PubMed Central) · doi:10.3779/j.issn.1009-3419.2012.02.08 · Cited by 3
Therapeutic impact of epidermal growth factor receptor tyrosine kinase inhibitor with various treatment combinations for advanced lung adenocarcinoma
Chen, Y., Lin, K., Kuo, Y., Tsai, Y.-M., Huang, H., & Huang, T.-W. (2023) · World Journal of Surgical Oncology · doi:10.1186/s12957-023-03203-6 · Cited by 3
Signaling dynamics in coexisting monoclonal cell subpopulations unveil mechanisms of resistance to anti-cancer compounds
Blanchard, C., Gomeiz, A., Avery, K., Gazzah, E. E., Alsubaie, A. M., Sikaroodi, M., Chiari, Y., Ward, C., Sanchez, J., Espina, V. A., et al. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01742-3 · Cited by 3
Solid Predominant Histology and High Podoplanin Expression in Cancer-Associated Fibroblast Predict Primary Resistance to Osimertinib in EGFR-Mutated Lung Adenocarcinoma
Uehara, Y., Izumi, H., Taki, T., Sakai, T., Udagawa, H., Sugiyama, E., Umemura, S., Zenke, Y., Matsumoto, S., Yoh, K., et al. (2024) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2024.100779 · Cited by 3
SH005S7 Overcomes Primary and Acquired Resistance of Non‐Small Cell Lung Cancer by Combined MET/EGFR/HER3 Inhibition
Kang, S., Kim, J. H., Hong, J., Moon, J. H., Kwon, Y. Y., & Ko, S. (2022) · BioMed Research International · doi:10.1155/2022/1840541 · Cited by 3
The Role of HGF/c-MET in Head and Neck Squamous Cell Carcinoma
Seiwert, T. Y., Beck, T. N., & Salgia, R. (2014) · Springer eBooks · doi:10.1007/978-1-4614-8815-6_5 · Cited by 3
SPSB1 May Have MET Its Match during Breast Cancer Recurrence
Qin, Y., & McAllister, S. S. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0505 · Cited by 3
EGFR inhibition generates drug-tolerant persister cells by blocking AKT activity
(2015) · Cancer Cell & Microenvironment · doi:10.14800/ccm.1045 · Cited by 3
Genetic interactions in translational research on cancer
Fang, B. (2011) · World Journal of Medical Genetics · doi:10.5496/wjmg.v1.i1.14 · Cited by 3
Detection and characterization of circulating cell free tumor DNA in cancer patients with malignant solid tumors. Liquid biopsy: a new tool in molecular pathology?
Hinrichsen, T., Dworniczak, J. K., Wachter, O., Dworniczak, B., & Dockhorn‐Dworniczak, B. (2016) · Journal of Laboratory Medicine · doi:10.1515/labmed-2016-0035 · Cited by 3
[Effect of clinical pathways based on integrative medicine for patients with chronic heart failure: a multi-center research].
Zou, X., Pan, G., Sheng, X.-G., Yao, G., Zhu, M., Wu, Y., Chen, X., Wang, Y., Cui, J., & Chen, J.-D. (2013) · PubMed · Cited by 3
Self-citation
Multi-modal single-cell and whole-genome sequencing of minute, frozen specimens to propel clinical applicationsPreprint
Wang, Y., Fan, J. L., Melms, J. C., Amin, A. D., Georgis, Y., Ho, P., Tagore, S., Abril-Rodríguez, G., Biermann, J., Hofree, M., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.02.13.480272 · Cited by 3
Farnesyltransferase inhibition overcomes the adaptive resistance to osimertinib in EGFR -mutant NSCLCPreprint
Figarol, S., Delahaye, C., Gence, R., Asslan, R., Pagano, S., Tardy, C., Colinge, J., Villemin, J.-P., Maraver, A., Ferrer, I., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.04.01.486707 · Cited by 3
Immune and Genomic Heterogeneity of MET-Altered Non–Small Cell Lung Cancer
Liu, M., Minne, R. L., Javeri, S., Johnson, D. B., Tomlins, S. A., Kimple, R. J., & Baschnagel, A. M. (2025) · JCO Precision Oncology · doi:10.1200/po-25-00048 · Cited by 2
Molecular Pathology of Lung Cancers
Sholl, L. M., & Lindeman, N. I. (2012) · Springer eBooks · doi:10.1007/978-1-4614-4900-3_5 · Cited by 2
Self-citation
Curative effect analysis of different treatments for gefitinib-resistance advanced non-small cell lung cancer patients.
Shi, H., Zhang, X., Wang, F., & Liu, D. (2015) · PubMed · Cited by 2
c-MET in Head and Neck Squamous Cell Carcinoma
Kaczmar, J. M., & Beck, T. N. (2018) · Current cancer research · doi:10.1007/978-3-319-78762-6_3 · Cited by 2
Adenocarcinoma
Kerr, K. M. (2012) · Molecular pathology library · doi:10.1007/978-1-4614-3197-8_13 · Cited by 2
Management and Treatment of Non-small Cell Lung Cancer with MET Alteration and Mechanisms of Resistance
Moiseenko, F. V., Bogdanov, A. A., Egorenkov, V. V., Волков, Н. М., & Moiseyenko, V. M. (2022) · Current Treatment Options in Oncology · doi:10.1007/s11864-022-01019-2 · Cited by 2
Response to capmatinib in a patient with neuroendocrine carcinoma of the gallbladder origin harboring MET amplification
Yamamura, S., Kanai, M., Takeuchi, Y., Okita, N. T., Kondo, T., Yoshioka, M., Matsubara, J., Matsumoto, S., & Muto, M. (2024) · International Cancer Conference Journal · doi:10.1007/s13691-023-00643-5 · Cited by 2
Pre-existing cell subpopulations in primary prostate cancer tumors display surface fingerprints of docetaxel-resistant cells
Drápela, S., Kvokačková, B., Slabáková, E., Kotrbova, A. V., Gömöryová, K., Fedr, R., Kurfürstová, D., Eliáš, M., Študent, V., Lenčéšová, F., et al. (2024) · Cellular Oncology · doi:10.1007/s13402-024-00982-2 · Cited by 2
Molecular Targeted Therapies in Head and Neck Cancer
Gondi, V., Traynor, A. M., & Harari, P. M. (2011) · Springer eBooks · doi:10.1007/978-1-4419-9464-6_20 · Cited by 2
537 Absolute quantitation of MET using mass spectrometry for clinical application: assay precision, stability, and correlation with MET gene amplification in FFPE tumor tissue
Cecchi, F., Liao, W. L., Thyparambil, S. P., Bengali, K. M., Uzzell, J. P., Darflar, M., Krizman, D. B., Burrows, J., Hembrough, T., Veenstra, T. D., et al. (2014) · European Journal of Cancer · doi:10.1016/s0959-8049(14)70663-x · Cited by 2
Unlocking Pandora's box: personalising cancer cell death in non-small cell lung cancer
Fennell, D. A., & Swanton, C. (2012) · The EPMA Journal · doi:10.1186/1878-5085-3-6 · Cited by 2
Clonality: A New Marker for Gastric Cancer Survival
Song, F., Chen, K., & Zhang, W. (2015) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2015.08.002 · Cited by 2
Intratumoral heterogeneity and biomarkers for transformation into small cell lung carcinomas from lung adenocarcinomas
Lee, H. J., & Um, S. (2017) · Journal of Thoracic Disease · doi:10.21037/jtd.2017.10.91 · Cited by 2
TTB2 induces apoptosis in Ewing sarcoma cells
Zou, X., & Huang, W. (2018) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2018.6236 · Cited by 2
Taxotere Induces Dephosphorylation of MET in Patient-derived Tumor Models
Mun, H., Lee, S.-H., Lee, C., Jo, S., Oh, J., Lee, A.-R., Lee, B., Jang, S. J., & Suh, Y. (2019) · Anticancer Research · doi:10.21873/anticanres.13932 · Cited by 2
Self-citation
Resistance to Anti-Cancer Therapeutics
Woyach, J. A. (2019) · Springer eBooks · doi:10.1007/978-3-030-23637-3_5 · Cited by 2
Résistances aux thérapeutiques ciblées et stratégies des lignes ultérieures dans les CBNPC métastatiques
Brosseau, S., Oulkhouir, Y., Naltet, C., & Zalcman, G. (2015) · Bulletin du Cancer · doi:10.1016/s0007-4551(15)31215-7 · Cited by 2
Toward Personalized Therapy for Cancer
Holder, A. M., & Meric‐Bernstam, F. (2015) · doi:10.1002/9781118468678.ch1 · Cited by 2
Evolution and clinical impact of genetic epistasis within EGFR-mutant lung cancersPreprint
Blakely, C. M., Watkins, T. B. K., Wu, W., Gini, B., Chabon, J. J., McCoach, C. E., McGranahan, N., Wilson, G. A., Birkbak, N. J., Olivas, V. R., et al. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/117291 · Cited by 2
CRISPR-barcoding in non small cell lung cancer: from intratumor genetic heterogeneity modeling to cancer therapy application
Marino, F. Z., Accardo, M., & Franco, R. (2017) · Journal of Thoracic Disease · doi:10.21037/jtd.2017.06.27 · Cited by 2
Application of Circulating Cell‐free DNA for Personalized Cancer Therapy
Chattopadhyay, I. (2020) · Wiley eBooks · doi:10.1002/9781119432487.ch3 · Cited by 2
Lung adenocarcinoma
Rosell, R. (2012) · doi:10.2217/ebo.12.11 · Cited by 2
Proto-oncogenes Crosstalk, Feedback and Expression, and Anticancer Drugs Resistance
Elalfy, M. M., Elhadidy, M. G., & Nashar, E. M. E. (2023) · Archives of Pharmacology and Therapeutics · doi:10.33696/pharmacol.4.040 · Cited by 1
HRA00129-C004, a Novel c-Met Antibody–Drug Conjugate, Exerts Encouraging Antitumor Activities and Favorable Safety Profiles
Tian, Y., Zhang, J., Sun, X., Yang, C., & Liao, C. (2025) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-24-0680 · Cited by 1

Authors: Turke, A. B., Zejnullahu, K., Wu, Y.-L., Song, Y., Dias-Santagata, D., Lifshits, E., Toschi, L., Rogers, A., Mok, T., Sequist, L., Lindeman, N. I., Murphy, C., Akhavanfard, S., Yeap, B. Y., Xiao, Y., Capelletti, M., Iafrate, A. J., Lee, C., Christensen, J. G., Engelman, J. A., & Jänne, P. A.
Affiliations: Harvard University (US)
Dana-Farber Cancer Institute (US)
Guangdong General Hospital (CN)
Massachusetts General Hospital (US)
Chinese University of Hong Kong (HK)
Brigham and Women's Hospital (US)
Pfizer (United States) (US)
Corresponding author: Engelman, Jeffrey A.
ORCID: Wu, Yi-Long
Song, Youngchul
Dias-Santagata, Dora
Toschi, Luca
Mok, Tony
Sequist, Lecia
Lindeman, Neal I.
Akhavanfard, Sara
Yeap, Beow Y.
Capelletti, Marzia
Iafrate, A. John
Lee, Charles
Christensen, James G.
Engelman, Jeffrey A.
Venue: Cancer Cell
Publisher: Elsevier BV
Published: 2010-01
Volume: 17
Issue: 1
Pages: 77-88
ISSN: 1535-6108 (ISSN-L)
DOI: 10.1016/j.ccr.2009.11.022
PMC: PMC2980857
OpenAlex: W1985264867
Cited by: 1,059
References: 37
Citations by year: 2026: 22 · 2025: 31 · 2024: 36 · 2023: 58 · 2022: 41 · 2021: 55 · 2020: 41 · 2019: 56 · 2018: 66 · 2017: 73 · 2016: 93 · 2015: 84 · 2014: 88 · 2013: 94 · 2012: 106
FWCI: 83.75
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 1293 d)
Locations: Cancer Cell (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: Guangdong Provincial Hospital of Traditional Chinese Medicine
University of Hong Kong
Chinese University of Hong Kong
National Institutes of Health
National Cancer Institute (P50CA127003, R01CA140594, R01CA114465, P50CA090578, R01CA135257, K08CA120060, R01CA137008)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Keywords: MET amplification, EGFR mutation, non-small cell lung cancer, hepatocyte growth factor, clonal selection, combination therapy
MeSH terms: Animals, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Gene Amplification, Humans, Lung Neoplasms, Mutation, Proto-Oncogene Proteins, Signal Transduction, Gene Expression, Polymerase Chain Reaction, Hepatocyte Growth Factor, In Situ Hybridization, Fluorescence, Receptors, Growth Factor, Drug Resistance, Neoplasm, Proto-Oncogene Proteins c-met, Xenograft Model Antitumor Assays, Cell Line, Tumor, Mice, Quinazolinones, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks